Auspherix Provides Update on its New Class of Organogold Antibiotics
Auspherix have provided an update on the development of their organogold antibiotic compounds, which have a unique chemical structure and a distinct antibacterial profile. The anti-infectives company have used their chemistry expertise to develop novel chemical compounds based on auranofin which inhibit both Gram-positive and Gram-negative bacteria.
Preliminary data indicates that Auspherix’s organogold compounds possess a broad spectrum of activity against both Gram-positive and Gram-negative bacteria (including life threatening multi-drug resistant (MDR) pathogens) and show less propensity for the emergence of resistance.
Some years ago the team at Auspherix embarked on a discovery program to identify antibacterial compounds. This research identified auranofin, an FDA approved anti-rheumatic agent, as having activity against Gram-positive bacteria in planktonic, biofilm and persister forms.
A press release from Auspherix can be found here.